GLPwatch
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
NCT01910194 · Completed
Last updated 2026-05-28This clinical trial tested the effects of combining Lantus (insulin glargine) and Lyxumia (lixisenatide) on insulin secretion and stomach emptying in adults with diabetes.
Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) study
Participants 39 people
Who can join Ages 18+ · all sexes
Timeline Started 2013-12 · est. completion 2014-10
Where 2 sites · Germany
What this study is testing ClinicalTrials.gov NCT01910194 ↗
Description as written by the study sponsor.
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Treatments tested
- Luyxumia versus Lantus Drug
| Main thing measured | AUCISEC(0-10min) |
|---|---|
| Sponsor | Profil Institut für Stoffwechselforschung GmbH |
| Conditions studied | Diabetes Mellitus |
| GLP-1 drugs | lixisenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01910194 ↗